These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1658605)

  • 1. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
    Riou JF; Helissey P; Grondard L; Giorgi-Renault S
    Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
    Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
    Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
    Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory activities against topoisomerase I and II by isoaurostatin derivatives and their structure-activity relationships.
    Suzuki K; Okawara T; Higashijima T; Yokomizo K; Mizushima T; Otsuka M
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2065-8. PubMed ID: 15808469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties.
    Har-Vardi I; Mali R; Breietman M; Sonin Y; Albotiano S; Levitas E; Potashnik G; Priel E
    Hum Reprod; 2007 Aug; 22(8):2183-9. PubMed ID: 17656417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
    Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
    Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
    Tseng CH; Tzeng CC; Yang CL; Lu PJ; Chen HL; Li HY; Chuang YC; Yang CN; Chen YL
    J Med Chem; 2010 Aug; 53(16):6164-79. PubMed ID: 20662543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC; Ashorn CL; Chan D; Zwelling LA
    Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
    Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
    Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel use for the comet assay: detection of topoisomerase II inhibitors.
    Salti GI; Das Gupta TK; Constantinou AI
    Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
    Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, topoisomerase I inhibitory activity and in vitro cytotoxicity of camptothecin derivatives bearing five-membered heterocycle containing 10-substituents.
    Zhao R; Guan LL; Oreski B; Lown JW
    Anticancer Drug Des; 1998 Mar; 13(2):145-57. PubMed ID: 9524556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of yerba mate (Ilex paraguariensis) tea on topoisomerase inhibition and oral carcinoma cell proliferation.
    Gonzalez de Mejia E; Song YS; Ramirez-Mares MV; Kobayashi H
    J Agric Food Chem; 2005 Mar; 53(6):1966-73. PubMed ID: 15769122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.